Table 1.
Included Studies
| Study | Scalp cooling | No scalp cooling | Length of follow-up (months) scalp cooling median | Weighted length of follow-up scalp cooling | Length of follow-up (months) no scalp cooling median | Weighted length of follow-up no scalp cooling | Characteristics | ||
|---|---|---|---|---|---|---|---|---|---|
| Scalp mets | Total pts | Scalp mets | Total pats | ||||||
| Lemieux et al. [11] | 6 | 553 | 1 | 87 | 69 | 19.478 | 64 | 4.498 | First time breast cancer patients. Study undertaken in Canada. Mainly T1 and T2 tumor size; stage 1 & 2, treated with mainly cyclophosphamides and doxorubicin |
| Parker [14] | 0 | 6 | 12 | 0.037 | Stage 4 recurrent disease. Treated with IV CMF (2 cycles) | ||||
| Protiere et al. [18] | 0 | 77 | 0 | 109 | 44 | 1.729 | First time breast cancer patients. 4 cycles of adjuvant IV chemotherapy with mitoxantrone + cyclophosphamide. Antiemetics also administered. Study undertaken in France | ||
| Ridderheim [15] | 0 | 3 | 15 | 0.023 | Adjuvant treatment breast cancer | ||||
| Ron et al. [19] | 0 | 19 | 0 | 16 | 14 | 0.136 | 14 | 0.181 | Breast cancer patients treated with cyclophosphamide, methotrexate, and 5- fluorouracil [CMF]; unclear as to stage of breast cancer |
| Rugo [17] | 0 | 101 | 29.5 | 1.521 | Early-stage breast cancer patients | ||||
| Spaëth et al. [20] | 3 | 770 | 0 | 141 | 36 | 14.150 | 36 | 4.100 | 93% breast cancer patients. Treated with IV chemo mainly anthracyclines and/or taxotere. Unclear as to stage of breast cancer |
| Tollenaar et al. [35] | 0 | 35 | 46 | 0.822 | Patients treated with cyclophosphamide + doxorubicin + 5-fluorouracil on first operative day (one course of treatment). Unclear as to stage of cancer | ||||
| van de Sande [12] | 4 | 885 | 110 | 78.635 | Stage 4 + lymph nodes | ||||
| van den Hurk et al. [13] | 3 | 395 | 26 | 5.242 | treated with CMF; unclear as to stage of breast cancer | ||||
| Totals | 12 | 1959 | 5 | 1238 | |||||
| Averages | 32.39 | 43.14 | 56 | 87.41 | |||||